Merck & Co., Inc.

MRKNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
124.03 USD
↗ 0.49 (0.40%)AT CLOSE (11:59 AM EDT)
123.94
↘ 0.09 (0.07%)
POST MARKET (AS OF 06:58 PM EDT)
Post Market
AS OF 06:58 PM EDT
123.94
↘ 0.09 (0.07%)
🟢Market: OPEN

Merck & Co., Inc. (MRK) trades at $123.94 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place MRK at a fair price relative to peers.

Technical & fundamental data as of Jul 13, 2026.

Open?$123.58
High?$124.74
Low?$122.44
Prev. Close?$123.54
Volume?5.2M
Avg. Volume?11.8M
VWAP?$123.70
Rel. Volume?0.44x
Bid / Ask
Bid?$123.68 × 100
Ask?$124.20 × 300
Spread?$0.52
Midpoint?$123.94
Valuation & Ratios
Market Cap?305.1B
Shares Out?2.5B
Float?2.4B
Float %?98.2%
P/E Ratio?34.15
P/B Ratio?6.65
EPS?$3.62
Dividend?2.70%
Ex-Dividend?N/A
News
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Infectious Disease & Vaccines
Employees
75.0K
Market Cap
305.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.merck.com
Listed
1949-04-20
Address
126 EAST LINCOLN AVENUE
RAHWAY, NJ 07065
Phone: 908-740-4000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
90
Momentum?
8
Short Sent.?
64
Piotroski F-Score?1/9Weak
Altman Z-Score?3.83Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.29%Low
Short Interest?31.4M
Days to Cover?2.3
Free Float2.4B
Avg Daily Volume13.6M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.30Adequate
Quick Ratio?1.06Adequate
Cash Ratio?0.20Low
Debt/Equity?1.07Moderate
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
61/100
P/E?
Peers
40
S&P
24
34.2PRICEY▾
P/B?
Peers
60
S&P
28
6.65FAIR▾
P/S?
Peers
82
S&P
32
4.64FAIR▾
P/FCF?
Peers
56
S&P
50
21.6FAIR▾
EV/EBITDA?
Peers
50
S&P
33
18.2FAIR▾
EV/Sales?
Peers
82
S&P
33
5.31FAIR▾
Returns & Efficiency
ROE?
Peers
33
S&P
65
19.5%STRONG▾
ROA?
Peers
40
S&P
60
6.9%FAIR▾
Cash Flow & Enterprise
FCF?$14.1B
Enterprise Value?$348.9B
Fundamentals ratios updated end of day
MarketsMoversWatchlist